


REMARKS

Upon entry of this amendment, claims 1-12 will be pending in the application. Claims 3 and 4 been amended to conform them to U.S. practice. Claims 10-12 have been amended to depend from claim 1. Claims 13 and 14 have been cancelled.

The Applicants reserve the right to prosecute, in this or another patent application, any subject matter originally claimed, and any other claims supported by the specification.

If it would facilitate the prosecution of this application, the Examiner is invited to confer with the Applicants' undersigned attorney.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090  
N:\kls\cases\p32672c1\prelim.doc

ABSTRACT

A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt, or a pharmaceutically acceptable solvate thereof, characterised in that the sodium salt is non-hygroscopic or slightly hygroscopic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine.